Heparin-Releasable Endothelial Cell-Associated Tissue Factor Pathway Inhibitor (Tfpi) is Increased in the Coronary Circulation After Coronary Spasm in Patients with Coronary Spastic Angina

1998 ◽  
Vol 89 (3) ◽  
pp. 137-146 ◽  
Author(s):  
K Nishiyama ◽  
H Ogawa ◽  
H Yasue ◽  
H Soejima ◽  
K Misumi ◽  
...  
Keyword(s):  
Endothelial Cell ◽  
Tissue Factor ◽  
Tissue Factor Pathway Inhibitor ◽  
Coronary Circulation ◽  
Coronary Spasm ◽  
Tissue Factor Pathway

Tissue factor pathway inhibitor (TFPI) interferes with endothelial cell migration by inhibition of both the Erk pathway and focal adhesion proteins

2008 ◽  
Vol 99 (03) ◽  
pp. 576-585 ◽  
Author(s):  
Mathieu Provençal ◽  
Marisol Michaud ◽  
Édith Beaulieu ◽  
David Ratel ◽  
Georges-Étienne Rivard ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Cell Migration ◽  
Endothelial Cell ◽  
Tissue Factor ◽  
Focal Adhesion ◽  
Tissue Factor Pathway Inhibitor ◽  
Endothelial Cell Migration ◽  
Cell Functions ◽  
Tissue Factor Pathway

SummaryTissue factor pathway inhibitor (TFPI) is a plasma Kunitz-type serine protease inhibitor that is mainly known for its inhibition of tissue factor-mediated coagulation. In addition to its anticoagulant properties, emerging data show that TFPI may also regulate endothelial cell functions via a non-haemostatic pathway. In this work we demonstrate that at concentrations within the physiological range,TFPI inhibits both endothelial cell migration and their differentiation into capillary-like structures in vitro. These effects were specific to endothelial cells since no inhibitory effect was observed on the migration of tumor (glio- blastoma) cells. Inhibition of endothelial cell migration was correlated with a concomitant loss in cell adhesion,suggesting an alteration of focal adhesion complex integrity. Accordingly,we observed thatTFPI inhibited the phosphorylation of focal adhesion kinase and paxillin,two key proteins involved in the scaffolding of these complexes, and that this effect was specific to endothelial cells. These results suggest that TFPI influences the angiogenic process via a non-haemostatic pathway, by downregulating the migratory mechanisms of endothelial cells.

Decreased Plasma Tissue Factor Pathway Inhibitor Levels in Patients with Thrombotic Thrombocytopenic Purpura

1995 ◽  
Vol 73 (01) ◽  
pp. 010-014 ◽  
Author(s):  
Hideo Wada ◽  
Masayuki Kobayashi ◽  
Yoshihiro Wakita ◽  
Minori Shimura ◽  
Tutomu Nakase ◽  
...  
Keyword(s):  
Endothelial Cell ◽  
Healthy Volunteers ◽  
Tissue Factor ◽  
Thrombotic Thrombocytopenic Purpura ◽  
Plasma Levels ◽  
Tissue Factor Pathway Inhibitor ◽  
Vascular Endothelial Cell ◽  
Vascular Endothelial ◽  
Thrombocytopenic Purpura ◽  
Tissue Factor Pathway

SummaryWe measured plasma levels of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in patients with thrombotic thrombocytopenic purpura (TTP) and disseminated intravascular coagulation (DIC) to examine the relationship between TFPI and vascular endothelial cell injury. TF antigen was detected in the plasma of healthy volunteers, and the levels were significantly increased in the patients with DIC, but decreased slightly in those with TTP. Plasma TFPI levels were significantly decreased in patients with TTP compared with those in healthy volunteers. The concentration of plasma thrombomodulin (TM) antigen was significantly higher in those with TTP than in normal volunteers. One month after treatment, TTP patients showed a significant decrease in plasma TM levels, and a significant increase, in plasma TFPI levels, but plasma levels of TF antigen were not significantly increased. As plasma TFPI/TF ratio was significantly increased after treatment, the hypercoagulable state was therefore improved after treatment. There was no significant difference in plasma TF and TFPI levels between those who achieved complete remission (CR) and those who died. However, plasma TM levels were significantly higher in those who died than in those who achieved CR. Plasma TFPI levels might reflect injury of vascular endothelial cells as do plasma TM levels, and decreased plasma TFPI/TF ratio and vascular endothelial cell injuries might play causative roles in TTP.

scholarly journals Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis

Blood ◽  
2010 ◽  
Vol 116 (10) ◽  
pp. 1787-1794 ◽  
Author(s):  
Thomas A. White ◽  
Tucker Johnson ◽  
Natalia Zarzhevsky ◽  
Cindy Tom ◽  
Sinny Delacroix ◽  
...  
Keyword(s):  
Endothelial Cell ◽  
Cell Surface ◽  
Tissue Factor ◽  
Knockout Mice ◽  
Arterial Thrombosis ◽  
Tissue Factor Pathway Inhibitor ◽  
Conditional Knockout ◽  
Endothelial Cell Surface ◽  
Tissue Factor Pathway ◽  
Exon 4

AbstractThe antithrombotic surface of endothelium is regulated in a coordinated manner. Tissue factor pathway inhibitor (TFPI) localized at the endothelial cell surface regulates the production of FXa by inhibiting the TF/VIIa complex. Systemic homozygotic deletion of the first Kunitz (K1) domain of TFPI results in intrauterine lethality in mice. Here we define the cellular sources of TFPI and their role in development, hemostasis, and thrombosis using TFPI conditional knockout mice. We used a Cre-lox strategy and generated mice with a floxed exon 4 (TFPIFlox) which encodes for the TFPI-K1 domain. Mice bred into Tie2-Cre and LysM-Cre lines to delete TFPI-K1 in endothelial (TFPITie2) and myelomonocytic (TFPILysM) cells resulted in viable and fertile offspring. Plasma TFPI activity was reduced in the TFPITie2 (71% ± 0.9%, P < .001) and TFPILysM (19% ± 0.6%, P < .001) compared with TFPIFlox littermate controls. Tail and cuticle bleeding were unaffected. However, TFPITie2 mice but not TFPILysM mice had increased ferric chloride–induced arterial thrombosis. Taken together, the data reveal distinct roles for endothelial- and myelomonocytic-derived TFPI.

scholarly journals Involvement of Tissue Factor Pathway Inhibitor in the Coronary Circulation of Patients With Acute Coronary Syndromes

Circulation ◽  
2003 ◽  
Vol 108 (23) ◽  
pp. 2864-2869 ◽  
Author(s):  
Paolo Golino ◽  
Amelia Ravera ◽  
Massimo Ragni ◽  
Plinio Cirillo ◽  
Orlando Piro ◽  
...  
Keyword(s):  
Tissue Factor ◽  
Acute Coronary Syndromes ◽  
Tissue Factor Pathway Inhibitor ◽  
Coronary Circulation ◽  
Coronary Syndromes ◽  
Tissue Factor Pathway

Endothelial cell-anchored tissue factor pathway inhibitor regulates tumor metastasis to the lung in mice

2015 ◽  
Vol 55 (5) ◽  
pp. 882-896 ◽  
Author(s):  
Jiping Wang ◽  
Jiajun Xiao ◽  
Danping Wen ◽  
Xie Wu ◽  
Zuohua Mao ◽  
...  
Keyword(s):  
Endothelial Cell ◽  
Tissue Factor ◽  
Tumor Metastasis ◽  
Tissue Factor Pathway Inhibitor ◽  
Tissue Factor Pathway

Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor

2004 ◽  
Vol 92 (09) ◽  
pp. 627-633 ◽  
Author(s):  
S. Mohamed ◽  
Shaker Mousa
Keyword(s):  
Molecular Weight ◽  
Endothelial Cell ◽  
Tissue Factor ◽  
Tissue Factor Pathway Inhibitor ◽  
Factor Xa ◽  
Tube Formation ◽  
Low Molecular Weight ◽  
Dependent Manner ◽  
Endothelial Tube Formation ◽  
Tissue Factor Pathway

SummaryHeparin and low molecular weight heparins (LMWHs) have both antithrombotic and anti-angiogenic activities. The antiangiogenic activity of LMWH may be associated with the release of endothelial tissue factor pathway inhibitor (TFPI), an important endogenous inhibitor of tissue factor/Factor VIIa (TF/fVIIa).To evaluate the effects of LMWH, tinzaparin, and TFPI in a model of angiogenesis-mediated processes, we compared the effects of tinzaparin, and recombinant TFPI in inhibiting either basic fibroblast growth factor-2 (FGF2) or TF/fVIIainduced endothelial cell tube formation in human umbilical vein endothelial cells (HUVEC).Our results show that tinzaparin and recombinant TFPI both blocked endothelial tube formation induced by either FGF2 or TF/fVIIa, in a concentration-dependent manner. Endothelial tube formation was only marginally inhibited by a potent and specific anti-Factor Xa, recombinant tick anticoagulant protein (rTAP). A monoclonal anti-TFPI antibody reversed the inhibitory effects of either tinzaparin or recombinant-TFPI on HUVEC tube formation. Tinzaparin fractions in the range of 8,000 to 12,600 Da were most effective in stimulating the release of TFPI from HUVEC. These results suggest that the inhibitory effect of the LMWH tinzaparin on endothelial tube formation is associated with stimulation of the release of TFPI, but not to anti-Factor Xa activity.

Sign in / Sign up

Export Citation Format

Share Document